FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022567999> ?p ?o ?g. }

• W3022567999 abstract "Abstract The study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of COVID-19 in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls from Zheijang, China we tested the role of usage of cardiovascular, antidiabetic and other medications on risk and severity of COVID 19. Analyses were adjusted for age, sex and BMI and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk [odds ratio (OR)= 1.73 (95% CI 1.2-2.3)] of manifesting symptoms of COVID-19 whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR=0.22; 95%CI 0.15-0.30 and OR=0.30; 95%CI 0.19-0.58 respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors (OR= 6.02; 95% CI 2.3-15.5) and insulin (OR= 2.71; 95% CI 1.6-5.5) were more and glucosidase inhibitors were less prevalent (OR= 0.11; 95% CI 0.1-0.3) among with COVID-19 patients. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but, not its severity. Study highlights What is the current knowledge on the topic? Cardiovascular disease and Diabetes have been highlighted as comorbidities contributing to a more severe form of COVID-19 and medication to treat them may also influence the risk of COVID-19 and its clinical outcomes. What question did this study address? Does specific medications used in the treatment of chronic diseases influence the risk for the susceptibility to SARS CoV-2 infection of severity of COVID-19? What does this study add to our knowledge? The study confirms that higher BMI, diabetes and cardio/ cerebrovascular disease as independent risk factors for the development of COVID-19. Angtiotensin Receptor Blockers (ARBs) and diuretics were associated with reduced risk and Calcium Channel Blockers (CCBs) with increased risk of developing COVID-19. Among those with type 2 diabetes, dipeptidyl peptidase-4 and were associated with increased and glucosidase inhibitors with reduced risk development of COVID-19. None of the antihypertensive or anti-diabetic drugs were associated with increased risk of severe or critical form of the infection. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but are not associated with severity of the disease. How might this change clinical pharmacology or translational science? Findings from the current large case-control study confirmed no evidence to alter ARBs or ACEIs therapy in the context of COVID-19 severity in clinical practice. Hypertension significantly increases the risk of severe or critical SARS-CoV-2 infection indicating that carefully controlled blood pressure should be a priority to reduce the healthcare burden of COVID-19." @default.
• W3022567999 created "2020-05-13" @default.
• W3022567999 creator A5000030927 @default.
• W3022567999 creator A5004718762 @default.
• W3022567999 creator A5007204344 @default.
• W3022567999 creator A5010069875 @default.
• W3022567999 creator A5012441370 @default.
• W3022567999 creator A5016096698 @default.
• W3022567999 creator A5034272890 @default.
• W3022567999 creator A5035199886 @default.
• W3022567999 creator A5037909354 @default.
• W3022567999 creator A5043337963 @default.
• W3022567999 creator A5056106034 @default.
• W3022567999 creator A5060613485 @default.
• W3022567999 creator A5061651350 @default.
• W3022567999 creator A5064190054 @default.
• W3022567999 creator A5076075825 @default.
• W3022567999 creator A5078594803 @default.
• W3022567999 creator A5080982384 @default.
• W3022567999 date "2020-04-29" @default.
• W3022567999 modified "2023-09-24" @default.
• W3022567999 title "Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study" @default.
• W3022567999 cites W1974590102 @default.
• W3022567999 cites W1980655557 @default.
• W3022567999 cites W2028521865 @default.
• W3022567999 cites W2040717081 @default.
• W3022567999 cites W2091671824 @default.
• W3022567999 cites W2129053556 @default.
• W3022567999 cites W2167384912 @default.
• W3022567999 cites W2315546057 @default.
• W3022567999 cites W2793955071 @default.
• W3022567999 cites W2794042305 @default.
• W3022567999 cites W2806885108 @default.
• W3022567999 cites W2811140330 @default.
• W3022567999 cites W2898243549 @default.
• W3022567999 cites W2996187220 @default.
• W3022567999 cites W3001118548 @default.
• W3022567999 cites W3003585850 @default.
• W3022567999 cites W3008028633 @default.
• W3022567999 cites W3008090866 @default.
• W3022567999 cites W3008827533 @default.
• W3022567999 cites W3009799538 @default.
• W3022567999 cites W3009912996 @default.
• W3022567999 cites W3012088820 @default.
• W3022567999 cites W3012285389 @default.
• W3022567999 cites W3012590443 @default.
• W3022567999 cites W3012696170 @default.
• W3022567999 cites W3012974177 @default.
• W3022567999 cites W3013197114 @default.
• W3022567999 cites W3013302817 @default.
• W3022567999 cites W3014194455 @default.
• W3022567999 cites W3016572296 @default.
• W3022567999 cites W3023751598 @default.
• W3022567999 cites W3024420022 @default.
• W3022567999 doi "https://doi.org/10.1101/2020.04.24.20077875" @default.
• W3022567999 hasPublicationYear "2020" @default.
• W3022567999 type Work @default.
• W3022567999 sameAs 3022567999 @default.
• W3022567999 citedByCount "12" @default.
• W3022567999 countsByYear W30225679992020 @default.
• W3022567999 countsByYear W30225679992021 @default.
• W3022567999 crossrefType "posted-content" @default.
• W3022567999 hasAuthorship W3022567999A5000030927 @default.
• W3022567999 hasAuthorship W3022567999A5004718762 @default.
• W3022567999 hasAuthorship W3022567999A5007204344 @default.
• W3022567999 hasAuthorship W3022567999A5010069875 @default.
• W3022567999 hasAuthorship W3022567999A5012441370 @default.
• W3022567999 hasAuthorship W3022567999A5016096698 @default.
• W3022567999 hasAuthorship W3022567999A5034272890 @default.
• W3022567999 hasAuthorship W3022567999A5035199886 @default.
• W3022567999 hasAuthorship W3022567999A5037909354 @default.
• W3022567999 hasAuthorship W3022567999A5043337963 @default.
• W3022567999 hasAuthorship W3022567999A5056106034 @default.
• W3022567999 hasAuthorship W3022567999A5060613485 @default.
• W3022567999 hasAuthorship W3022567999A5061651350 @default.
• W3022567999 hasAuthorship W3022567999A5064190054 @default.
• W3022567999 hasAuthorship W3022567999A5076075825 @default.
• W3022567999 hasAuthorship W3022567999A5078594803 @default.
• W3022567999 hasAuthorship W3022567999A5080982384 @default.
• W3022567999 hasBestOaLocation W30225679991 @default.
• W3022567999 hasConcept C126322002 @default.
• W3022567999 hasConcept C134018914 @default.
• W3022567999 hasConcept C146304588 @default.
• W3022567999 hasConcept C156957248 @default.
• W3022567999 hasConcept C201903717 @default.
• W3022567999 hasConcept C2777180221 @default.
• W3022567999 hasConcept C2779134260 @default.
• W3022567999 hasConcept C2779159551 @default.
• W3022567999 hasConcept C2908647359 @default.
• W3022567999 hasConcept C3008058167 @default.
• W3022567999 hasConcept C524204448 @default.
• W3022567999 hasConcept C555293320 @default.
• W3022567999 hasConcept C71924100 @default.
• W3022567999 hasConcept C72563966 @default.
• W3022567999 hasConcept C99454951 @default.
• W3022567999 hasConceptScore W3022567999C126322002 @default.
• W3022567999 hasConceptScore W3022567999C134018914 @default.
• W3022567999 hasConceptScore W3022567999C146304588 @default.
• W3022567999 hasConceptScore W3022567999C156957248 @default.
• W3022567999 hasConceptScore W3022567999C201903717 @default.

• next